Populating an economic model with health state utility values: moving toward better practice
- PMID: 20230546
- DOI: 10.1111/j.1524-4733.2010.00700.x
Populating an economic model with health state utility values: moving toward better practice
Abstract
Background: The methods used to estimate health-state utility values (HSUV) for multiple health conditions can produce very different values. Economic results generated using baselines of perfect health are not comparable with those generated using baselines adjusted to reflect the HSUVs associated with the health condition. Despite this, there is no guidance on the preferred techniques and little research describing the effect on cost per quality adjusted life-year (QALY) results when using the different methods.
Methods: Using a cardiovascular disease (CVD) model and cost per QALY thresholds, we assess the consequence of using different baseline health-state utility profiles (perfect health, no history of CVD, general population) in conjunction with models (minimum, additive, multiplicative) frequently used to approximate scores for health states with multiple health conditions. HSUVs are calculated using the EQ-5D UK preference-based algorithm.
Results: Assuming a baseline of perfect health ignores the natural decline in quality of life associated with age, overestimating the benefits of treatment. The results generated using baselines from the general population are comparable to those obtained using baselines from individuals with no history of CVD. The minimum model biases results in favor of younger-aged cohorts. The additive and multiplicative models give similar results.
Conclusion: Although further research in additional health conditions is required to support our findings, our results highlight the need for analysts to conform to an agreed reference case. We demonstrate that in CVD, if data are not available from individuals without the health condition, HSUVs from the general population provide a reasonable approximation.
Similar articles
-
NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models [Internet].London: National Institute for Health and Care Excellence (NICE); 2011 Jul. London: National Institute for Health and Care Excellence (NICE); 2011 Jul. PMID: 28481493 Free Books & Documents. Review.
-
Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods.Med Care. 2012 May;50(5):452-9. doi: 10.1097/MLR.0b013e318234a04a. Med Care. 2012. PMID: 22002647
-
Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.Clin Ther. 2009 Dec;31(12):2919-30; discussion 2916-8. doi: 10.1016/j.clinthera.2009.12.013. Clin Ther. 2009. PMID: 20110032
-
Using health state utility values in models exploring the cost-effectiveness of health technologies.Value Health. 2012 Sep-Oct;15(6):971-4. doi: 10.1016/j.jval.2012.05.003. Epub 2012 Jun 15. Value Health. 2012. PMID: 22999149 Review.
-
Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health.Pediatrics. 2005 May;115(5):e600-14. doi: 10.1542/peds.2004-2127. Pediatrics. 2005. PMID: 15867026 Review.
Cited by
-
The Challenge for Orphan Drugs Remains: Three Case Studies Demonstrating the Impact of Changes to NICE Methods and Processes and Alternative Mechanisms to Value Orphan Products.Pharmacoecon Open. 2023 Mar;7(2):175-187. doi: 10.1007/s41669-022-00378-8. Epub 2022 Oct 31. Pharmacoecon Open. 2023. PMID: 36315388 Free PMC article.
-
Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK.Pharmacoecon Open. 2024 Nov;8(6):923-934. doi: 10.1007/s41669-024-00520-8. Epub 2024 Aug 28. Pharmacoecon Open. 2024. PMID: 39196476 Free PMC article.
-
Health impact of rotavirus vaccination in China.Hum Vaccin Immunother. 2024 Dec 31;20(1):2386750. doi: 10.1080/21645515.2024.2386750. Epub 2024 Sep 13. Hum Vaccin Immunother. 2024. PMID: 39269780 Free PMC article.
-
Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece.Rheumatol Int. 2015 Sep;35(9):1489-95. doi: 10.1007/s00296-015-3253-x. Epub 2015 Mar 21. Rheumatol Int. 2015. PMID: 25794569
-
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton's Tyrosine Kinase Inhibitor in Canada.Curr Oncol. 2022 Mar 17;29(3):2021-2045. doi: 10.3390/curroncol29030164. Curr Oncol. 2022. PMID: 35323364 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources